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Abstract
Background: Variant ATM heterozygotes have an increased risk of developing cancer, cardiovascular diseases,
and diabetes. Costs and time of sequencing and ATM variant complexity make large-scale, general population
screenings not cost-effective yet. Recently, we developed a straightforward, rapid, and inexpensive test based
on p53 mitotic centrosomal localization (p53-MCL) in peripheral blood mononuclear cells (PBMCs) that diagnoses
mutant ATM zygosity and recognizes tumor-associated ATM polymorphisms.
Methods: Fresh PBMCs from 496 cancer patients were analyzed by p53-MCL: 90 cases with familial BRCA1/2-
positive and -negative breast and/or ovarian cancer, 337 with sporadic cancers (ovarian, lung, colon, and
post-menopausal breast cancers), and 69 with breast/thyroid cancer. Variants were confirmed by ATM
sequencing.
Results: A total of seven individuals with ATM variants were identified, 5/65 (7.7 %) in breast cancer cases
of familial breast and/or ovarian cancer and 2/69 (2.9 %) in breast/thyroid cancer. No variant ATM carriers
were found among the other cancer cases. Excluding a single case in which both BRCA1 and ATM were
mutated, no p53-MCL alterations were observed in BRCA1/2-positive cases.
Conclusions: These data validate p53-MCL as reliable and specific test for germline ATM variants,
confirm ATM as breast cancer susceptibility gene, and highlight a possible association with breast/thyroid
cancers.
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Background
Biallelic mutations in the ATM gene cause Ataxia-
telangiectasia (A-T), a rare autosomal recessive multisys-
temic disorder characterized by progressive cerebellar
ataxia, immune defects, insulin-resistant diabetes, radio-
sensitivity, and high risk for malignancy [1, 2]. The ATM
gene spans approximately 160 Kb of genomic DNA con-
taining 66 exons [3] and encodes ATM protein, a serine/
threonine kinase mainly involved in DNA damage
response pathways following DNA double strand breaks
[4]. An enormous number of mutations (more than 600)
can occur in the coding and noncoding regions of the
ATM gene without hotspots [5]. In A-T patients, the large
majority of ATM mutations are protein-truncations or
splice-junction variants that can be easily distinguished by
the numerous ATM polymorphisms [6, 7].
Heterozygous carriers of variants in the ATM gene
(from here on, ATM carriers) are usually asymptomatic
and largely considered healthy carriers. However, they
have been reported to be more sensitive to ionizing radi-
ation and susceptible to ischemic heart disease, diabetes,
and cancer, particularly of the breast, but also digestive
tract and lung [2, 8]. Many association studies have been
performed on breast cancer susceptibility. Initially,
epidemiological studies on relatives of A-T patients re-
vealed a two to fivefold increased in the risk of breast
cancer for female obligate ATM carriers [9]. The in-
creased risk of breast cancer in ATM carriers was then
confirmed by direct ATM sequencing in breast cancer
cases compared to controls [10] and ATM is now con-
sidered a moderate-penetrance cancer susceptibility gene
in BRCA1/2-negative patients with familial early-onset
breast cancer [11]. Along with A-T associated muta-
tions, several ATM screenings in cancer patients iden-
tified missense ATM variants, particularly amino acid
substitutions that are not expected to be associated
with A-T [12]. However, discrimination of these ATM
variants from ATM polymorphisms and their contri-
bution to health risks is still controversial. In
addition, distinguishing between deleterious and neu-
tral ATM alterations is required to allow the defin-
ition of standard-of-care clinical guidelines for the
management of ATM carriers and their families [11].
Systematic review and meta-analysis of ATM sequen-
cing data have been conducted to evaluate the health
risks for parents and siblings of A-T patients, but
similar large-scale screenings for ATM carriers in the
general population by direct sequencing are not cost-
effective yet [13].
Recently, we have developed a rapid, reliable and non-
expensive test based on the ATM-dependent p53-
mitotic centrosomal localization (p53-MCL) that clearly
discriminates ATM carriers of A-T mutations and at
least some of the ATM cancer predisposition variants in
lymphoblastoid cell lines (LCLs) and PBMCs. At vari-
ance with other diagnostic tests, the p53-MCL assay
does not measure a continuous quantitative variation
(e.g., radiosensitivity, ATM protein levels, phosphoryl-
ation of ATM targets) but a “binary” outcome. Indeed, at
the single cell level, p53 does or does not localize at the
centrosomes while, at the cell-population level, the num-
ber of cells showing one or the other phenotype allows
to unambiguously diagnose A-T homozygotes and ATM
carriers [14].
In a preliminary set up and validation of the p53-MCL
test, we showed that it is highly sensitive, specific, and
precise. In particular, we assessed the specificity by ana-
lyzing LCLs from monogenic disease carrying mutations
in a series of DNA-damage related factors, such as
MRE11, NBS1, SMC1A, WRN, ATR, FANC-A, and p53
[14]. In addition, p53-MCL test revealed 7 ATM carriers
among 80 sporadic breast cancer patients. By direct
ATM sequencing of 3 of these carriers, we identified the
cancer-prone intronic c.8786 + 8A > C variant [15] in
one patient and the c.2572 T > C (p.F858L) missense
mutation [16] in other two patients. No ATM carriers
were observed in a comparable cohort of healthy donors
[14]. These data support p53-MCL as promising candi-
date test for cost-effective, large-scale screenings of
ATM carriers.
Here, we examined validity and specificity of p53-
MCL analyzing 15 LCLs from familial breast and
ovarian cancer cases and fresh PBMCs from a total of
496 cases including BRCA1/2-positive and -negative
familial breast and ovarian cancer and different spor-
adic cancers.
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Methods
Patients
A total of 496 cancer patients were enrolled from 2010
to 2015 at three different Italian institutes: Policlinico
Umberto I (University La Sapienza), Sant’Andrea Hos-
pital (University La Sapienza), and Regina Elena National
Cancer Institute - IRCCS. In particular, according to pre-
viously described criteria [17], we selected 90 unrelated
families affected with breast and/or ovarian cancer after
interview at the Hereditary Tumors Counseling Centre
of the Policlinico Umberto I. Pre-test counseling was
performed by an expert cancer risk counselor and the
probands analyzed in this study belonged to different
high-risk classes. During the genetic counseling, we cal-
culated the a priori probability of carrying a pathogenic
BRCA1/2 germline mutation by the statistical model
BRCAPRO that considers: proband health state (un/af-
fected); current age and age at diagnosis of the proband
and all family members of four consecutive generations
(only first/second degree relatives); typology of the exist-
ent tumors (unilateral/bilateral breast cancer, other can-
cers) [18]. Then, 69 patients with breast and thyroid
cancer regardless of the sequence of appearance were
recruited from Sant’Andrea Hospital and Regina Elena
National Cancer Institute. Others 337 patients unse-
lected cancer patients diagnosed at any age were
recruited from Regina Elena National Cancer Institute.
Cells and culture conditions
EBV-immortalized LCLs and freshly isolated PBMCs
were cultured in RPMI-1640 GlutaMAX supplemented
with 15 % heat-inactivated fetal bovine serum, 100 U/ml
penicillin, and 100 μg/ml streptomycin (all from Invitro-
gen, CA, USA). PBMCs were isolated from donors’ hep-
arinized blood samples by Lympholyte-H (Cedarlane,
Burlington, USA) density gradient centrifugation. PBMCs
were stimulated to proliferate by incubation with 5 μg/ml
PHA (Sigma-Aldrich, St. Louis, MO, USA) and incubated
at 37 °C in a 5 % CO2 atm for 60 h [14].
p53-MCL test
Proliferating cells (i.e., LCLs or PHA-stimulated PBMCs)
were set up for p53-MCL test as previously described
[14]. Cells were examined under an Olympus BX53
microscope equipped with epifluorescence. Percentages
of p53-MCL were measured by counting 100 cells in
metaphase and analyzing two coverslips for each sample.
The percentage of p53 mitotic localization is from 75 to
90 % for normal subjects, from 40 to 55 % for ATM
carriers, and from 0 to 30 % for A-T patients.
BRCA1/2 gene sequencing
Genomic DNA was extracted from peripheral blood of
all probands using commercial kit (Qiamp Blood Kit,
Qiagen, Hilden, Germany). The entire coding sequence
and each intron/exon boundary of BRCA1 and BRCA2
were screened by direct sequencing. All truncating and/
or novel genetic variants were confirmed by sequencing
different samples on both DNA strands. Sequencing was
performed using the BigDye Terminator v3.1 Cycle Se-
quencing Kit and a 3130xl Genetic Analyzer (Applied
Biosystems, CA, USA). Reference sequence for BRCA1
was Genebank NM_007294.3, NG_005905.2 and reference
sequence for BRCA2 was Genebank, NM_000059.3,
NG_012772.3. BRCA1/2 genomic rearrangements were
searched by the Multiple Ligation dependent Probe Amp-
lification (MLPA) methodology. MLPA procedure was
carried out according to the manufacturer’s instructions.
Variations in peak height were evaluated comparing each
sample with a normal control and by a cumulative
comparison.
ATM gene sequencing
Genomic DNA was extracted from PBMCs by Quick-
gDNA MiniPrep (Zymo Research, CA, USA) according
to the manufacturer’s instructions. Sixty-two ATM exons
were amplified using AmpliTaq Gold (Applied Biosys-
tems, CA, USA), as described [14], and subjected to dir-
ect sequencing at the Genechron Laboratory (Rome,
Italy). Reference sequence for ATM was Genebank
U82828.1.
In silico analysis
To predict possible impact of amino acid substitutions
on the structure and function of human proteins, the
PolyPhen-2 (Polymorphism Phenotyping v2) software,
that uses straightforward physical and evolutionary com-
parative considerations [19], was employed.
Efficient splicing of many exons requires splicing-
enhancers to promote splicing at unfavorable splice-sites
or splicing-silencers to repress more favorable splice-sites
nearby. As a consequence, single nucleotide changes in an
exon or intron close to these splice-sites may be predicted
to disrupt splicing. For in silico prediction of the effects of
mutations on normal splicing, the interactive biosoftware
Alamut v2.3 [20] was adopted.
Statistic
We determined statistical significance of differences be-
tween two groups by 2-tailed Student’s t test. P values
less than 0.01 were considered significant.
Results
Beyond the high penetrance BRCA1/2 genes, mutations
of several cancer susceptibility genes, including ATM,
CHK2 and PALB2, have been shown to associate, with a
moderate penetrance, with familial breast and/or ovarian
cancers [21, 22]. Thus, we first verified p53-MCL test
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specificity compared to mutant BRCA1/2 and CHK2
proteins that are also involved in DNA damage response
and centrosome amplification and localization [23–25].
LCLs from 15 familial breast and ovarian cancer
(Table 1) including four BRCA1-positive, 2 BRCA2-
positive, 1 CHK2-positive and 8 BRCA1/2/CHK2/
PALB2-negative LCLs were analyzed by the p53-MCL
test. As shown in Table 1 and Fig. 1a, the percentage of
p53-MCL was compatible with that of wild-type cells in
13 out of 15 LCLs, while two cases showed a p53-MCL
reduction typical of ATM carriers, one in a BRCA1-
positive case and the other in a BRCA1/2/CHK2/
PALB2-negative case. Direct ATM sequencing confirmed
the presence of ATM variants (Table 1) in both cases
demonstrating p53-MCL specificity for ATM variants
also in comparison with mutations in the centrosome re-
lated factors BRCA1/2 and CHK2.
Next, we analyzed 90 cases of familial breast and/or
ovarian cancer (Table 2). All 90 patients were screened
for mutations in the BRCA1 and BRCA2 genes and 20
were found to carry pathogenic variants with an overall
mutation rate of 22.2 % (Table 2). In particular BRCA1
pathogenic mutation recurred in about 26 % (8/30) of
the Hereditary Breast and Ovarian Cancer (HBOC) fam-
ilies and in about 7 % (4/60) of the Hereditary Breast
Cancer (HBC) families, while BRCA2 pathogenic muta-
tion occurred in about 13 % (4/30) and 7 % (4/60) of
the HBOC and HBC families, respectively. Of the 20
mutation-positive probands, 11 had breast cancer
alone (5 BRCA1 and 6 BRCA2), three had ovarian
cancer alone (3 BRCA1), three had bilateral breast
cancer (2 BRCA1 and 1 BRCA2), two had both breast
and ovarian cancer (1 BRCA1 and 1 BRCA2) and one
had both bilateral breast and ovarian cancer (BRCA1).
When fresh PBMCs from BRCA1/2-positive and
-negative patients were analyzed by the p53-MCL test,
five out of 90 cases showed aberrant p53-MCL
(Fig. 1b). Interestingly p53-MCL positive cases
accounted for 6.6 and 5 % of the HBOC and HBC
families, respectively (Table 2). Of note, this rate is
similar to that of BRCA2 mutations [26].
The five individuals with ATM variants identified by
the p53-MCL test were all breast cancer patients (5/65,
7.7 %). Four of them were BRCA1/2 negative patients
and one was a BRCA1 positive patient (Fig. 2). No ATM
carriers were detected by p53-MCL in patients with
ovarian cancer, bilateral breast cancer, or multiple
Table 1 Genetic status and p53-MCL rate of LCLs from familial
breast and ovarian cancer
BRCA1 BRCA2 CHK2 PALB2 ATM p53-MCL%
BR36 wt mut nt nt nt 80
BR13 wt mut nt nt nt 76
BR409-3 mut wt nt nt nt 97
BR324-1 mut wt nt nt nt 85
BR404-1 mut wt wt wt wt 76
BR317 mut wt nt nt mut 50
BR377 wt wt wt wt mut 50
BR60-1 wt wt wt wt wt 71
BR107-1 wt wt wt wt wt 90
BR362-1 wt wt wt wt wt 92
BR494 wt wt wt wt wt 86
BR38 wt wt wt wt wt 91
BR48 wt wt wt wt wt 70
BR278-1 wt wt wt wt wt 80
BR501 wt wt mut wt wt 80
wt wild type, mut mutated, nt not tested
Fig. 1 p53-MCL in LCLs and in PBMCs from familial breast and/or ovarian BRCA1/2-positive and –negative patients. (a) Comparison of p53-MCL
percentages, among LCLs derived from wild type ATM donors (CTR, n = 11), BRCA1/2-negative (n = 7), BRCA1/2-positive (n = 5), CHK2-positive (n
= 1), and ATM variants carriers (n = 2) and ATM carriers (n = 9) previously tested. Not significant differences among the groups including wild type
ATM (CTR, BRCA1/2-neg, BRCA1/2-pos and CHK2-pos), but significant differences between these groups and ATM carriers groups (ATM variants
and ATM carriers). (b) Comparison of p53-MCL percentages among PBMCs from familial breast and/or ovarian BRCA1/2-positive, BRCA1/2–nega-
tive and ATM carrier patients. Not significant differences between BRCA1/2-positive and -negative patients, but significant differences between
wild type ATM group (BRCA1/2-positive and -negative) and ATM carriers. ***P < 0.0001; NS = Not Significant; 2-tailed Student’s t test
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cancers (breast cancer and at least one other non-breast
cancer) (n = 27) (Table 3).
Besides early onset-breast cancer, ATM carriers have
been reported to be more susceptible to other types of
cancer, such as digestive tract, lung, and thyroid cancers
[2, 8]. Thus, we performed the p53-MCL test on fresh
PBMCs from 403 patients with sporadic cancers, includ-
ing ovarian (n = 49), lung (n = 150), colon (n = 80), post-
menopausal breast (n = 58), and both breast/thyroid (n =
69) cancer. Two individuals with ATM variants were
identified among breast/thyroid cancer cases (2/69, 2.9)
(Table 4). No ATM carriers were found in sporadic ovar-
ian cancer (0/49), non-small cell lung cancer (0/150),
colorectal cancer (0/80), and post-menopausal breast
cancer (0/58).
As shown in Fig. 2 and Additional file 1: Table S1, 11 dif-
ferent ATM variants were detected among the 9 p53-MCL
positive cases (i.e., 2 LCLs and 7 PBMCs). Specifically, in
breast cancer cases, patient #1 presents c.4578C >T and
c.1899-55 T >G variants. The c.4578C > T was previously
described [27] and corresponds to a synonymous substitu-
tion (P1526P), which is predicted to create a new exonic
site with increased affinity for the SRp55 splicing factor by
an in silico analysis (Fig. 3a). The c.1899-55 T >G is a pre-
viously described intronic variant [28] predicted to increase
the affinity for the SRp40 splicing factor (Fig. 3b). Patient
#2 presents two variants not previously described in the lit-
erature nor in the ATM variation database (c.908A >C and
c.5919-49C > T). Our in silico analyses predict a higher
affinity for the splicing factor SC35, for both variants
(Fig. 3c, d). The c.5557G >A (D1853N) variant presents in
patient #3 is predicted to be “possibly damaging” by the
PolyPhen-2 tool and has been intensively studied with
respect to its possible association with breast cancer sus-
ceptibility [29]. Patient #4 and patient #5 present two dele-
terious variants, c.824delT and c.8833delCT, that induce
early protein truncation at the level of exon 9 and 63, re-
spectively, which have already been described in ATM
families [30, 31]. In the breast and thyroid cancer cases, pa-
tient #6 presents two already described variants, c.3161C >
G and c.3576G >A. The c.3161C >G (P1054R) is a substi-
tution predicted to be “possibly damaging” by PolyPhen-2
and implicated in breast and prostate cancer risk [32]. The
c.3576G >A variant leads to exon 26 skipping and causes
A-T syndrome in homozygosis [30]. Patient #7 presents
the intronic variant c.4436 + 24A >G that in silico analyses
predict a mild higher affinity for the splicing factors SC35
and SRp55 (Fig. 3e). LCLs BR317 presents c.146C >G
(S49C) variant, a substitution predicted to be possibly dam-
aging by PolyPhen-2 and reported as breast cancer suscep-
tibility variant [16]. Finally, LCLs BR377 presents the same
c.3161C >G (P1054R) variant found in patient #6.
Discussion
Genetic susceptibility plays an important role in several
common chronic diseases including many types of can-
cer. Genetic testing for large-scale, general population
screening can be very expensive and non-cost effective
for National Health Services. Concerning the ATM gene,
the complex genomic organization, the large number of
polymorphisms, the absence of mutation hot-spots, and
the frequent occurrence of variants of yet uncharacter-
ized but predicted deleterious functions, make direct
gene sequencing not yet a cost-effective approach. This
is particularly evident for large-scale surveys of mutant/
variant ATM carriers for which gene sequencing is not
sufficient to classify the rare hits. All these factors hinder
both genetic counseling and clinical guidelines for risk
management of ATM carriers and their families. The
use of the recently developed p53-MCL functional test
to detect ATM carriers might overcome at least some of
these limitations. Here, we established the p53-MCL
specificity for ATM in respect to the high-risk, BRCA1/2
breast/ovarian cancer susceptibility genes and confirmed
p53-MCL as reliable test to detect variant ATM carriers
in cancer patients.
BRCA1/2 and ATM proteins share functional activ-
ities both in DNA damage response pathways and in
centrosome regulation [33]. Thus, it was mandatory
to establish whether a functional test, such as the
p53-MCL test, would discriminate between ATM and
BRCA1/2 variant carriers. Analysis of BRCA1/2-posi-
tive LCLs (n = 6) and PBMCs (n = 20), and of 1
CHK2-positive LCL established the specificity of p53-
MCL test on ATM in respect to BRCA1/2 and CHK2
mutations (Table 1 and Fig. 1).
A total of seven individuals with ten ATM variants
were identified by p53-MCL test in PBMCs: five
breast cancer patients in HBC and HBOC families
and two breast/thyroid cancer patients. The finding
that all cases were among pre-menopausal breast
cancer cases but not among patients with post-





n = 20/90 (22.2 %)
ATM carriers
n = 5/90(5.5 %)
Age-years
Median 52.9 53.7 44.4
Range 30–82 40–75 32–51
Familial aggregation
HBOC 30 (33.3 %) BRCA1: 8/30 (26 %) 2/30 (6.6 %)
BRCA2: 4/30 (13 %)
HBC 60 (66.7 %) BRCA1: 4/60 (7 %) 3/60 (5 %)
BRCA2: 4/60 (7 %)
BRCAPRO 27.3 % 50.1 % 52.2 %
HBOC hereditary breast and ovarian cancer, HBC hereditary breast cancer
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Fig. 2 ATM variants in ATM carriers. Electropherograms showing ATM variants identified in PBMCs derived from five familial breast cancer (BC)
patients (BC patient#1/#5), two breast-thyorid cancer (BTC) patients (BTC patient#6/#7) and two LCLs (BR317; BR377). All sequences are compared
with wild-type reference sequence. Arrows indicates the position of the substitution and/or deletion
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menopausal breast cancer or ovarian cancer is con-
sistent with previous studies showing prevalence of
germline ATM mutations detected by sequencing in
patients with familial early-onset breast cancer [34] or
by p53-MCL in sporadic breast cancer [14]. Interest-
ingly, the a priori probability of carrying a pathogenic
BRCA1/2 germline mutation measured by the BRCA-
PRO score showed a mean for the entire cohort of
27.3 while the mean for the five ATM carriers was
52.2 % (Table 2). This difference is statistically signifi-
cant (P =0.01) and supports the presence of a strong
genetic component in the ATM carriers with early-
onset breast cancer, also considered that the BRCA-
PRO score for the BRCA positive cases is very similar
to ATM positive ones (50.1 % vs. 52.2 %).
Evaluation of the histopathologic features of the breast
cancers developed in the seven identified ATM carriers
showed the presence of estrogen and progesterone
receptors and the absence of HER2 receptor in four out
of five cases that have been tested (Tables 4 and 5), con-
firming our previous results [14]. Thus, the presence of
germline ATM variants recognized by p53-MCL appears
to identify a subset of tumors with a more favorable bio-
marker asset, despite their earlier onset. In addition, a
possible association between breast and thyroid cancer
was highlighted by the identification of two ATM car-
riers among the sporadic cancer patients with breast/
thyroid cancer (2/69, 2.9 %), encouraging for further
studies.
Familial breast and ovarian cancers are linked to
highly penetrant mutations in the BRCA1/2 suscepti-
bility genes that overall account for 20–25 % of her-
editary breast cancers and 15 % of ovarian cancers
[26]. Gene panel next generation sequencing ap-
proaches identified moderate-penetrant mutations in
the ATM gene in 2.9 % [11] and 2.3 % [34] of
BRCA1/2-negative cases. By the p53-MCL test, in this
study we found 5.5 % (5/90) of ATM mutation
Table 3 Histopathological characteristics of all cancer patients
Tumor type Cases n = 496 BRCA1/2 carriers n = 20 ATM carriers n = 7
Familial Cancer cases 90 20 5
Breast 65 (70.6 %) 11/65 (16.9 %) 5/65 (7.7 %)
Ovarian 8 (8.7 %) 3/8 (37.5 %) 0/8
Bilateral Breast 10 (10.9 %) 3/10 (30 %) 0/10
Breast-Ovarian 4 (4.3 %) 2/4 (50 %) 0/4
Colon-Breast 1 (1.1 %) 0/1 0/1
Uterin-Breast 1 (1.1 %) 0/1 0/1
Anal-Bilateral Breast 1 (1.1 %) 0/1 0/1
Bilateral Breast-Ovarian 1 (1.1 %) 1/1 (100 %) 0/1
Ipsilateral Breast 1 (1.1 %) 0/1 0/1
Sporadic cancer cases 406 - 2/406
Ovarian 49 - 0/49
Lung 150 - 0/150
Colon 80 - 0/80
Post-menopausal Breast 58 - 0/58
Breast/Thyroid 69 - 2/69 (2.9 %)
Table 4 Clinical and pathological characteristics of breast and
thyroid cancer patients








Ductal 59 (85.5 %) 1 (50 %)
Lobular 3 (4.3 %) 0
Unknown 7 (10.2 %) 1 (50 %)
ER status
Negative 17 (24.6 %) 0
Positive 34 (49.3 %) 2 (100 %)
Unknown 18 (26.1 %) 0
PgR status
Negative 17 (24.6 %) 0
Positive 34 (49.3 %) 2 (100 %)
Unknown 18 (26.1 %) 0
ER estrogen receptor, PgR progesterone receptor
Prodosmo et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:135 Page 7 of 10
carriers, which adds up to the 27.7 % (20/90) carrying
BRCA1/2 mutations. In particular, three ATM muta-
tions occurred among the 60 HBC cases, with a
mutation rate (5 %) very close to that observed for
BRCA2 (7 %) in the same subset. These observations
suggest that the fast and non-expensive p53-MCL test
should precede or be performed in parallel with
BRCA1/2 sequencing.
Most of the ATM mutations occurring in A-T
patients are frameshift or nonsense mutations leading
to protein truncation or splice junction variants [6, 7]
The role of A-T-causing mutations in cancer suscepti-
bility (in particular breast cancer) is still debated and
some studies have shown that a subset of rare, evolu-
tionarily unlikely missense substitutions are important
[15, 35, 36]. Here, the p53-MCL test identified 11
ATM variants in 9 breast and breast/thyroid patients.
Three variants (c.824delT; c.8833delCT; c.3576G > A)
identified in 3 different patients are known to cause
A-T in homozigosity [30, 31]. Other 3 variants
(c.5557G > A; c.146C > G; c.3161C > G) identified in 3
different patients have been shown to be associated
with an increased cancer risk [16, 29, 32]. The last 3
patients present 5 different variants (c.4578C > T;
c.1899-55 T > G; c.908A > C; c.5919-49C > T; c.4436 +
24A > G) that our in silico analysis predicted to in-
crease the affinity for splicing factor and modify alter-
native splicing activities. Whether these predicted
modifications alter ATM function/s and cancer pre-
disposition remain to be evaluated. Since loss of p53
centrosomal localization was the functional readout
through which we diagnosed the ATM carriers, we
can conclude that these variants are at least able to
impair the mitotic localization of p53 at the
Fig. 3 In silico analysis using Alamut software. ATM variants identified in PBMCs derived from two familial breast cancer patients (BC patient#1
and #2) and one breast-thyorid cancer patient (BTC patient#7) lead to an increased affinity and/or appearance of a de novo sites for SR proteins
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centrosomes. It will be relevant to study whether all
ATM variants induce this p53 defect or whether only
functionally relevant variants are able to impair p53-
MCL. Whether this impaired p53 localization has a
role in tumorigenesis is presently unknown. Studying
the mechanistic basis of p53 centrosomal localization
will give insights on the contribution that different
ATM variants with uncertain significance might have
in cancer predisposition. Application of the p53-MCL
test to LCLs or PBMCs with a broad spectrum of
ATM variants will help to define these issues.
Conclusions
Our results show that p53-MCL test may offer the
opportunity for screening of the general population
and to identify the differences among deleterious,
neutral and beneficial variants helping, in the future,
to define the guidelines for ATM carriers not only in
the A-T families.
Additional file
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